Video

Dr. Hutson on Safety Considerations With Cabozantinib in mRCC

Thomas Hutson, DO, PharmD, discusses key safety considerations with cabozantinib in patients with metastatic renal cell carcinoma.

Thomas Hutson, DO, PharmD, director, Urologic Oncology Program, co-chair, Urologic Cancer Research and Treatment Center, Baylor University Medical Center, professor of medicine, Texas A&M College of Medicine, discusses key safety considerations with cabozantinib (Cabometyx) in patients with metastatic renal cell carcinoma (mRCC).

Cabozantinib is a potential treatment option for patients with mRCC, says Hutson. Initially, patients receiving cabozantinib should be monitored every 2 to 3 weeks for blood pressure changes, mouth sores, diarrhea, and hypertension, Hutson explains. Once dosing and adverse effect (AE) management strategies are in place, patients can be monitored every 6 to 8 weeks, Hutson says.

Additionally, it is important to establish a relationship with the patient in which they feel comfortable relaying any AEs that arise and understand that dose reduction is an option, concludes Hutson.

Related Videos
Jonathan Spicer, MD, PhD, FRCS
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Binod Dhakal, MD
Sheldon M. Feldman, MD
Yair Lotan, MD, UT Southwestern Medical Center